Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy
Learn More About Aimmune
Innovative medicines for the treatment of hormonally-driven cancers.
Aisling congratulates the management teams of Aragon and Seragon on their recent acquisitions by Johnson & Johnson and Genentech, respectively.
learn moreLearn More About Aragon & Seragon
CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq
Largest provider of biopharmaceutical development and commercial outsourcing services.
Learn More About Quintiles
Dalvance™ for the treatment of acute bacterial skin and skin structure infections.
Aisling congratulates the management team of Durata on its recent acquisition by Actavis.
Learn More About Durata
Diagnostics to accurately identify sepsis pathogens in hours instead of days.
Learn More About T2 BiosystemsAisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.
See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn moreLatest News
AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease
July 15, 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 15, 2019-- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) today announced the first kidney biopsy result and additional positive data from two ongoing clinical trials of its AVR‑RD‑01…
READ MORE
Sunesis Announces Pricing of $25 Million Offering of Securities
July 11, 2019
SOUTH SAN FRANCISCO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333…
READ MORE
TransEnterix, Inc. Announces Sale of AutoLap Assets
July 10, 2019
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul. 10, 2019-- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive…
READ MORE